Kiehl’s Since 1851, the 166-year-old skincare company, has used its fleet of iconic motorcycles to raise funds and awareness for AIDS research and awareness for the eighth year in a row. Kiehl’s LifeRide for amfAR, a charitable motorcycle ride from Minneapolis to Nashville, July 31 to Aug. 7, has already raised more than $125,000 for amfAR, The Foundation for AIDS Research and fundraising will continue through August.
Kiehl’s President Chris Salgardo and amfAR CEO Kevin Robert Frost led the 1,200 mile, 8-day journey, accompanied by actors Tyler Posey, Gilles Marini and Ian Bohen, tattoo artist Luke Wessman, and TV hosts Anthony Carrino and Grant Reynolds. Over eight days, the riders participated in nine public events, meeting customers and educating about HIV/AIDS research.
To view the multimedia release go to:
https://www.multivu.com/players/English/8160451-kiehls-liferide-for-amfar-aids-research-liferide8/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
Building on a successful campaign that helped hundreds of thousands of Americans learn their risk of developing type 2 diabetes through campaign messaging and an online risk test, the first-of-its-kind initiative to raise national awareness of prediabetes returns with an entertaining new approach. The new campaign, launching today, encourages viewers to take a one-minute prediabetes risk test to know where they stand and discover how they can decrease their risk of developing type 2 diabetes — and it does so with some adorable helpers.
More than one in three American adults has prediabetes — a serious health condition that often leads to type 2 diabetes and other significant health conditions like blindness, heart attack or stroke. According to newly released CDC data, however, nearly 90 percent of the 84 million people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health. Currently, about 30 million Americans are living with diabetes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142351-ad-council-prediabetes/
The Lincoln Continental, the Mercedes-Benz E-Class and the Toyota Avalon come out at the top of a group of six large cars recently evaluated by the Insurance Institute for Highway Safety.
The three cars qualify for TOP SAFETY PICK+, the Institute’s highest award. The Tesla Model S, the Chevrolet Impala and the Ford Taurus fall short of any award because they each earn only an acceptable rating in the small overlap front test.
Vehicles qualify for either the TOP SAFETY PICK or TOP SAFETY PICK+ award if they have good ratings from IIHS in five crashworthiness tests — small overlap front, moderate overlap front, side, roof strength and head restraints — and an available front crash prevention system that earns a superior or advanced rating. To qualify for TOP SAFETY PICK+, a vehicle also must come with good or acceptable headlights
Jason’s Deli and The University of Texas MD Anderson Cancer Center proudly introduce the new Salmon Pacifica Salad as part of an ongoing alliance to raise money to help end cancer for patients and families around the world.
Now through April 2018, 50 cents from the sale of every Salmon Pacifica Salad at participating Jason’s Deli restaurants will be donated to MD Anderson to support cancer prevention research and programs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102251-jasons-deli-md-anderson-cancer-center-salmon-pacifica-salad/
Today, Johnson & Johnson, the world’s largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson & Johnson Our Story to take visitors on a journey through time and around the world as they explore the stories behind more than 130 years of innovations that have changed the course of human health.
To view the multimedia release go to:
https://www.multivu.com/players/English/8077331-jnj-our-story/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their stories – from inspirational successes to daily struggles. Thousands of people from across the country responded, and revealed common challenges like eating healthy, exercising, sticking to a treatment plan and coping with the disease.
“Type 2 diabetes has affected my family, friends and fans, so I’ve learned it can be challenging to manage. It was great to hear from so many people, and I’m impressed by everyone’s dedication to their health,” said McGraw. “The stories we received shed an important light on the similar hardships people in the community face as they work toward achieving their blood sugar goals.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7988751-merck-americas-diabetes-challenge-tim-mcgraw-s-epatha-merkerson-chef-leticia-moreinos-schwartz/
La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) alerta a las mujeres embarazadas sobre los riesgos de la listeriosis, una enfermedad transmitida por los alimentos que puede afectar gravemente a las mujeres embarazadas y a sus bebés no nacidos.
La Listeria puede afectar a personas de todas las razas y grupos étnicos, pero las mujeres embarazadas tienen una probabilidad aproximadamente 10 veces mayor de contraer listeriosis que otros adultos sanos debido a los cambios hormonales que afectan el sistema inmunológico durante el embarazo. Las mujeres hispanas embarazadas son unas 24 veces más propensas a contraer listeriosis que la población general. Una mujer embarazada puede transmitir la Listeria a su bebé no nacido incluso sin saberlo porque no se siente enferma, pero la enfermedad puede provocar un aborto espontáneo, muerte fetal, parto prematuro, nacimiento de un bebé con bajo peso, una amplia gama de problemas de salud para el recién nacido o incluso la muerte del bebé.
To view the multimedia release go to:
https://www.multivu.com/players/Spanish/7953451-fda-listeriosis-prevention-pregnant-women/
The U.S. Food and Drug Administration (FDA) is alerting pregnant women about the risks of listeriosis, a foodborne disease that can severely affect a pregnant women and her unborn child.
Listeria can affect all races and ethnic groups, but pregnant women are 10 times more likely than other healthy adults to get listeriosis due to hormonal changes that affect the immune system during pregnancy. Pregnant Hispanic women are about 24 times more likely than the general population to get listeriosis. A pregnant mother may pass Listeria onto her unborn baby without even knowing it because she doesn’t feel sick at all, yet the disease can lead to miscarriage, stillbirth, premature labor, the delivery of a low birthweight infant, a wide range of health problems for a newborn, or even infant death.
To view the multimedia release go to:
https://www.multivu.com/players/English/7953451-fda-listeriosis-prevention-pregnant-women/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
